Replies to post #429268 on Anavex Life Sciences Corp (AVXL)

[Joseph_K]

frrol, what do you mean by "If the missing data for those ORs are strong"?

[Steady_T]

AFAIK there were no OR endpoints.

There was OR given in the presentation in what appeared to me to be an illustrative manner to show improvement over baseline.

What evidence do you have to support you statement that the company is struggling with getting clear dose sub-grouping?
Titration by its nature leads to a data point spread. Since titration is not uncommon there must be ways of statistically dealing with it.

Biology is messy.

[bas2020]

Complete FUD nonsense...

Meeting those OR endpoints didn't mean anything,

It's clearly evident the ORs were included to highlight the Super Responders, who functionally IMPROVED.

Your "prognostications" are absolutely laughable. You don't know schitt about the data or what the regulators will or won't accept. So pathetic!

The way our AD trial would not lead to AA is firstly inadequate efficacy or biomarker support. If good but not great, our relatively small n will likely then be an issue for regulators.

FUDsters working hard to downplay the data and spin ridiculous narratives.
Biotech isn't for everyone.